Hua Chen

发表

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

A. Panoskaltsis-Mortari, D. Vallera, A. Sicheneder, 2009, Leukemia research.

131I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer.

Teng Liu, P. Pei, Hua Chen, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery

W. Hall, D. Vallera, J. Ohlfest, 2009, Journal of Neuro-Oncology.

Self-assembly of antibodies by chemical induction.

C. Wagner, D. Vallera, Qing Li, 2008, Angewandte Chemie.

Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

A. Frankel, D. Vallera, Hua Chen, 2010, Molecular Cancer Therapeutics.

A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma

D. Vallera, D. Todhunter, A. Sicheneder, 2005, Clinical Cancer Research.

ABispecific Recombinant Immunotoxin , DT 2219 , Targeting Human CD 19 and CD 22 Receptors in aMouse XenograftModel of B-Cell Leukemia / Lymphoma

D. Vallera, D. Todhunter, A. Sicheneder, 2005 .

Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv

B. Stish, D. Vallera, Hua Chen, 2007, Clinical Cancer Research.

Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.

D. Vallera, D. Todhunter, Vincent D. Vallera, 2005, Leukemia research.

A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer

B. Stish, D. Vallera, Hua Chen, 2007, Clinical Cancer Research.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

D. Vallera, J. Ohlfest, Alexander K. Tsai, 2011, Journal of Neuro-Oncology.

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

B. Stish, D. Sachdev, D. Vallera, 2009, Clinical Cancer Research.

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model

B. Stish, A. Saluja, S. Vickers, 2008, Gut.

Self-assembly of antibodies by chemical induction.

C. Wagner, D. Vallera, Qing Li, 2008, Angewandte Chemie.

Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

A. Frankel, D. Vallera, Hua Chen, 2010, Molecular Cancer Therapeutics.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

B. Stish, R. Kratzke, D. Vallera, 2009, British Journal of Cancer.